Selected References:
- Kasuya A, et al. 2019. Successful control of severe eosinophilic granulomatosis with polyangiitis in pregnancy and perinatal period: A use of mepolizumab. The Journal of Dermatology 46(9):e309-e311.
- Nucala® Prescribing Information. Revised 1/2022. Available online at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF.
- Shakuntulla F, Chiarella SE. 2022. Safety of Biologics for Atopic Diseases During Pregnancy. J Allergy Clin Immunol Pract.10(12):3149-3155.
- Sitek AN, et al. 2023. Risks and safety of biologics: A practical guide for allergists. World Allergy Organ J. 16(1):100737.
- Smith DA, et al. 2011. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 50(4):215–27.
- Vittorakis SK, et al. 2022. Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy. Respir Med Case Rep. 28;41:101785.
